Clinical labs lean on LIAISON SARS-CoV-2 TrimericS IgG for reliable antibody results

DiaSorin’s LIAISON SARS-CoV-2 TrimericS IgG assay remains a workhorse immunoassay for clinical labs that need quantitative COVID-19 antibody results, with FDA Emergency Use Authorization and broad analyzer compatibility keeping the test relevant in routine serology workflows.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 9:22 AM ET. Details in the imprint.

With hospitals and reference labs still running targeted COVID-19 serology, DiaSorin's LIAISON SARS-CoV-2 TrimericS IgG test has settled into the role of a dependable flagship antibody assay, offering quantitative IgG measurements against the spike protein’s trimeric structure on the company’s fully automated LIAISON platforms. The chemiluminescent immunoassay is authorized under the US Food and Drug Administration’s Emergency Use Authorization (EUA) for use on human serum and plasma, and it is CE marked for in vitro diagnostic use in Europe, giving laboratories a regulated framework for routine deployment. The FDA’s EUA summary describes the assay as a semi-quantitative test that detects IgG antibodies to the SARS-CoV-2 spike protein in samples from individuals with prior infection or vaccination.

What the LIAISON TrimericS IgG assay does for clinical labs

At the core of the product is DiaSorin’s chemiluminescence immunoassay (CLIA) technology, configured here to detect IgG antibodies directed against the native trimeric spike glycoprotein, which is presented in a conformation designed to mimic the structure found on the viral surface. According to DiaSorin’s own technical documentation, the LIAISON SARS-CoV-2 TrimericS IgG assay reports results in arbitrary units per milliliter (AU/mL) and is traceable to the World Health Organization International Standard, allowing labs to convert into binding antibody units (BAU/mL) using a manufacturer-provided factor for better comparability across platforms. DiaSorin states on the official product page that the test runs on LIAISON and LIAISON XL analyzers with a time to first result of about 35 minutes and sample throughput suited to high-volume routine workflows.

Clinical performance data submitted for regulatory review show that the assay achieved high sensitivity and specificity in samples collected at least two weeks after PCR-confirmed infection, which has made it attractive for post-infection seroprevalence studies and for monitoring antibody responses after vaccination when used within the limitations defined by regulators. European lab evaluations have reported good correlation between LIAISON TrimericS IgG and other spike-based immunoassays, although cutoffs and numerical values differ, underlining the need for clinicians to interpret results in the context of each laboratory’s reference ranges and local guidelines. Because the assay targets the spike protein instead of nucleocapsid, it can detect vaccine-induced IgG in addition to antibodies generated by natural infection, which has been valuable for occupational health programs and longitudinal cohort studies that follow antibody dynamics over time.

On the practical side, the test fits into the broader LIAISON ecosystem, which many hospital labs already use for infectious disease and endocrine panels, meaning staff can handle SARS-CoV-2 serology using familiar workflows, consumables and middleware interfaces. Sample volume requirements are relatively modest, allowing parallel testing for other markers from a single draw, and labs can store results in their laboratory information systems as semi-quantitative values for follow-up comparison. DiaSorin has positioned the TrimericS IgG reagent kit as part of a menu that also includes neutralizing antibody proxy assays and tests directed at other SARS-CoV-2 antigens, but the spike-focused IgG assay remains the anchor choice for many customers who need a single, well-characterized marker in routine use.

Market positioning and role in DiaSorin’s diagnostics portfolio

Within DiaSorin’s broader offering, SARS-CoV-2 serology sits alongside respiratory PCR panels, hepatitis markers and autoimmune tests, making the LIAISON TrimericS IgG an important connector between acute molecular diagnostics and longer-term immune monitoring. The company has emphasized to investors that COVID-19 products have shifted from pandemic surge volumes to a more stable, recurring demand pattern, with serology volumes now driven mainly by specialty uses such as immunocompromised patient management and vaccine study support rather than broad population screening. In recent communications with the financial community, DiaSorin has described its immunodiagnostics business as benefiting from menu breadth and installed base, with COVID-19 assays representing a smaller, but still meaningful, contribution within that mix. In its 2023 and early 2024 results presentations, the company highlighted its LIAISON immunoassay analyzers and SARS-CoV-2 solutions as drivers of recurring reagent revenue even as overall COVID-19 testing volumes normalize.

For laboratories making purchasing decisions, the appeal of the TrimericS IgG assay is less about headline innovation and more about stability: the product is backed by regulatory authorizations in major markets, supported by a sizable installed base of analyzers, and integrated into a vendor ecosystem that includes service contracts, remote support and quality control materials. Procurement teams can bundle SARS-CoV-2 serology reagents with broader DiaSorin test menus for conditions such as hepatitis, HIV and endocrine disorders, which can simplify negotiations and logistics. From a scientific perspective, the trimeric spike design and traceability to international standards make the assay suitable for many research-adjacent clinical applications, though formal neutralizing antibody tests or cellular immunity assays may be needed for specific use cases. As long as clinical guidelines and research protocols continue to call for quantitative spike IgG measurements on automated platforms, the LIAISON SARS-CoV-2 TrimericS IgG kit is likely to retain a visible, if more modest, place in serology benches.

DiaSorin, headquartered in Saluggia, Italy, continues to position itself as a specialized player in immunodiagnostics and molecular diagnostics, with COVID-19 tests now serving as one component of a diversified assay portfolio that spans infectious diseases, oncology and endocrinology. The company is publicly listed on the Borsa Italiana; its shares (ISIN IT0003497168) last closed on the Milan exchange at EUR 99.20 on 06/14/2026, according to market data compiled by Borsa Italiana.

LIAISON SARS-CoV-2 TrimericS IgG key facts

• Product: LIAISON SARS-CoV-2 TrimericS IgG
• Manufacturer: DiaSorin SpA
• Category: Flagship/Bestseller immunodiagnostic assay
• Launch date: Initial launch 2020 (pandemic period), subsequent updates and regional clearances in following years
• MSRP / Price: Not publicly disclosed; reagent kit pricing typically negotiated with clinical laboratories and hospital groups
• Availability: Authorized for use in multiple markets including the US under FDA EUA and Europe with CE-IVD marking; supplied through DiaSorin’s clinical diagnostics distribution network
• Target audience: Hospital and reference laboratories operating LIAISON family analyzers and needing quantitative SARS-CoV-2 spike IgG results
• Key differentiator / USP: Automated chemiluminescent assay targeting the native trimeric spike protein, traceable to WHO standards and integrated into DiaSorin’s high-throughput LIAISON platforms

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.